Unclear results for the use of botulinum toxin therapy for TMD pain.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
117 participants.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
All five studies were targeted primarily on the masseter and temporalis muscles and most of them administered injections at bilateral muscle sites.
[DATA SOURCES] A comprehensive search was carried out on major databases such as PubMed, EMBASE and Cochrane CENTRAL.
- 연구 설계 Meta-analysis
APA
Keenan JR (2015). Unclear results for the use of botulinum toxin therapy for TMD pain.. Evidence-based dentistry, 16(4), 122. https://doi.org/10.1038/sj.ebd.6401139
MLA
Keenan JR. "Unclear results for the use of botulinum toxin therapy for TMD pain.." Evidence-based dentistry, vol. 16, no. 4, 2015, pp. 122.
PMID
26680526 ↗
Abstract 한글 요약
[DATA SOURCES] A comprehensive search was carried out on major databases such as PubMed, EMBASE and Cochrane CENTRAL. Reference lists of the included studies were explored along with journals likely to contain studies relevant to the topic. The search was restricted to the English language.
[STUDY SELECTION] The inclusion criteria included randomised and quasi-randomised controlled trials including parallel or cross-over studies comparing botulinum toxin therapy (BTX) versus any alternative intervention or placebo.
[DATA EXTRACTION AND SYNTHESIS] Quality assessment and data extraction were done following the Cochrane risk of bias tool and recommendations. All of the steps in the review, including the search and selection process, were done independently by two reviewers. Disagreements were discussed with one another until consensus was reached.
[RESULTS] Five relevant studies were included in the review, which consisted of 117 participants. Two trials revealed a significant inter-group difference in myofascial pain reduction. Another trial that compared BTX with fascial manipulation showed no significant difference in pain relief for temporomandibular disorders (TMDs), while the remaining two trials showed no significant difference between the BTX and placebo groups. Meta-analysis was not performed due to the considerable variation in study methods and evaluation of the results. All five studies were targeted primarily on the masseter and temporalis muscles and most of them administered injections at bilateral muscle sites. The methods used to find the muscles to target were all based on physical examination, with three studies using electromyography (EMG) as guidance. The dose of BTX ranged from 70U to 300U, the majority used being 100-150U. All studies gave a single session of BTX and re-evaluated participants at least one month following the injection.
[CONCLUSIONS] No consensus could be reached on the therapeutic benefit of BTX on TMDs.
[STUDY SELECTION] The inclusion criteria included randomised and quasi-randomised controlled trials including parallel or cross-over studies comparing botulinum toxin therapy (BTX) versus any alternative intervention or placebo.
[DATA EXTRACTION AND SYNTHESIS] Quality assessment and data extraction were done following the Cochrane risk of bias tool and recommendations. All of the steps in the review, including the search and selection process, were done independently by two reviewers. Disagreements were discussed with one another until consensus was reached.
[RESULTS] Five relevant studies were included in the review, which consisted of 117 participants. Two trials revealed a significant inter-group difference in myofascial pain reduction. Another trial that compared BTX with fascial manipulation showed no significant difference in pain relief for temporomandibular disorders (TMDs), while the remaining two trials showed no significant difference between the BTX and placebo groups. Meta-analysis was not performed due to the considerable variation in study methods and evaluation of the results. All five studies were targeted primarily on the masseter and temporalis muscles and most of them administered injections at bilateral muscle sites. The methods used to find the muscles to target were all based on physical examination, with three studies using electromyography (EMG) as guidance. The dose of BTX ranged from 70U to 300U, the majority used being 100-150U. All studies gave a single session of BTX and re-evaluated participants at least one month following the injection.
[CONCLUSIONS] No consensus could be reached on the therapeutic benefit of BTX on TMDs.
추출된 의학 개체 (NER)
시술
보툴리눔독소 주사 ×2
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Impact of prior endoscopic or surgical interventions on clinical outcomes after peroral endoscopic myotomy for achalasia.
- Comprehensive treatment for intracranial invasive sinonasal intestinal-type adenocarcinoma with a focus on radiotherapy dosage and immunological combination therapy: A case report.
- Efficacy and Safety of Intratympanic Botulinum Toxin Injection on Middle Ear Myoclonic Tinnitus.
- Anticholinergic Burden and Botulinum Toxin Needs after Deep Brain Stimulation in Adult and Pediatric Patients with Dystonia.
- Optimal target localization for botulinum toxin A in treating splenius muscles dystonia based on the distribution of intramuscular nerves and spindles.
- Gastric-Type Cervical Adenocarcinoma: Clinicopathologic Features, Molecular Landscape, and Therapeutic Challenges.
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
- Mechanisms of Botulinum Toxin Type A Action on Pain.
- Effect of Botulinum Toxin Injection on EMG Activity and Bite Force in Masticatory Muscle Disorder: A Randomized Clinical Trial.
- Botulinum Toxin: An Update on Pharmacology and Newer Products in Development.
- Immunogenicity of botulinum toxin.
- Botulinum Toxin in the Treatment of Headache.